Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Approved drugs screening against the nsP1 capping enzyme of Venezuelan equine encephalitis virus using an immuno-based assay

  • Ferreira-Ramos, A. S.
  • Li, C.
  • Eydoux, C.
  • Contreras, J. M.
  • Morice, C.
  • Quérat, G.
  • Gigante, A.
  • Peréz-Pérez, María-Jesús
  • Jung, M. L.
  • Canard, B.
  • Guillemot, J. C.
  • Decroly, E.
  • Coutard, B.
Alphaviruses such as the Venezuelan equine encephalitis virus (VEEV) are important human emerging pathogens transmitted by mosquitoes. They possess a unique viral mRNA capping mechanism catalyzed by the viral non-structural protein nsP1, which is essential for virus replication. The alphaviruses capping starts by the methylation of a GTP molecule by the N7-guanine methyltransferase (MTase) activity; nsP1 then forms a covalent link with mGMP releasing pyrophosphate (GT reaction) and the mGMP is next transferred onto the 5′-diphosphate end of the viral mRNA to form a cap-0 structure. The cap-0 structure decreases the detection of foreign viral RNAs, prevents RNA degradation by cellular exonucleases, and promotes viral RNA translation into proteins. Additionally, reverse-genetic studies have demonstrated that viruses mutated in nsP1 catalytic residues are both impaired towards replication and attenuated. The nsP1 protein is thus considered an attractive antiviral target for drug discovery. We have previously demonstrated that the guanylylation of VEEV nsP1 can be monitored by Western blot analysis using an antibody recognizing the cap structure. In this study, we developed a high throughput ELISA screening assay to monitor the GT reaction through mGMP-nsP1 adduct quantitation. This assay was validated using known nsP1 inhibitors before screening 1220 approved compounds. 18 compounds inhibiting the nsP1 guanylylation were identified, and their IC determined. Compounds from two series were further characterized and shown to inhibit the nsP1 MTase activity. Conversely, these compounds barely inhibited a cellular MTase demonstrating their specificity towards nsP1. Analogues search and SAR were also initiated to identify the active pharmacophore features. Altogether the results show that this HT enzyme-based assay is a convenient way to select potent and specific hit compounds targeting the viral mRNA capping of Alphaviruses., This work was supported by the French research agency ANR “VMTaseIn”, grant ANR-ST14-ASTR-0026, and by the European Union (Seventh Framework Program, Marie Skłodowska-Curie ETN “EUVIRNA”, grant agreement number 264286 and Horizon 2020 Marie Skłodowska-Curie ETN “ANTIVIRALS”, grant agreement number 642434), and by the MINECO/FEDER SAF2015-64629-C2-1-R., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum

  • Martínez-Gualda, Belén
  • Sun, L.
  • Martí-Marí, Olaia
  • Mirabelli, C.
  • Delang, Leen
  • Neyts, Johan
  • Schols, Dominique
  • Camarasa Rius, María José
  • San-Félix, Ana
We have previously reported a new class of dendrimers with tryptophan (Trp) residues on the surface that show dual antiviral activities against HIV and enterovirus EV71. The prototype compound of this family is a derivative of pentaerythritol with 12 peripheral Trp groups and trivalent spacer arms. Here a novel series of dendrimers with divalent and tetravalent branched arms, instead of the trivalent ones present on the prototype, has been synthesized and its activity against HIV, EV71 and a panel of 16 different viruses and other pathogens has been determined. Convergent or divergent approaches have been used for the synthesis of these compounds. Our findings demonstrate that only compounds with tetravalent branched arms showed the same anti-HIV and anti-EV71 activity of the prototype (low micromolar) and even gain significant antiviral activity against new pathogens such as HSV-2, adenovirus-2, human corona virus and respiratory syncytial virus, being the first members of the Trp dendrimer family that showed activity against those viruses. As the prototype, these compounds also showed low-nanomolar activity against a representative EV71 clinical isolate. Experimental work carried on to determine the mode of action of the most potent IIa, containing tetravalent branched arms, demonstrated that it interacts with the viral envelopes of HIV, EV71 and HSV-2 and thus may prevent virus attachment to the host cell. These results support the interest of this new series of Trp dendrimers and qualify them as useful prototypes for the development of novel inhibitors of viral entry with broad antiviral spectrum., This work has been supported by the Spanish Ministerio de Economía, Industria y Competitividad (MINECO) [project SAF2015- 64629-C2-1-R (MINECO/FEDER)], the Spanish Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC, Project CSIC201680E079), “The Centers of Excellence” of the KU Leuven (EF- 05/15 and PF-10/18), EU FP7 (FP7/2007–2013) Project EUVIRNA (Grant 408 Agreement 264286), EU FP7 SILVER (Contract HEALTH-F3- 2010-260644), a grant from the Belgian Interuniversity Attraction Poles (IAP) Phase VII–P7/45 (BELVIR) and the EU FP7 Industry-Academia Partnerships and Pathways Project AIROPICO. The Spanish MEC/ MINECO is also acknowledged for a grant to B.M.G and the China Scholarship Council (Grant 201403250056) for a grant to L.S. We also thank Charlotte Vanderheydt, Caroline Collard, Kim Donckers, Sandra Claes and Evelyne Van Kerckhove for help with the processing of the antiviral data and Arnaud Boonen and Sam Noppen with the generation of the SPR data., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors

  • Martínez-Gualda, Belén
  • Sun, Liang
  • Martí-Marí, Olaia
  • Abdelnabi, Rana
  • Noppen, Sam
  • Bator, Carol M.
  • Quesada, Ernesto
  • Delang, Leen
  • Mirabelli, Carmen
  • Lee, Hyunwook
  • Schols, Dominique
  • Neyts, Johan
  • Hafenstein, Susan
  • Camarasa Rius, María José
  • Gago, Federico
  • San-Félix, Ana
Currently, there are only three FDA-approved drugs that inhibit human immunodeficiency virus (HIV) entry-fusion into host cells. The situation is even worse for enterovirus EV71 infection for which no antiviral therapies are available. We describe here the discovery of potent entry dual inhibitors of HIV and EV71. These compounds contain in their structure three or four tryptophan (Trp) residues linked to a central scaffold. Critical for anti-HIV/EV71 activity is the presence of extra phenyl rings, bearing one or two carboxylates, at the C2 position of the indole ring of each Trp residue. The most potent derivatives, 22 and 30, inhibit early steps of the replicative cycles of HIV-1 and EV-A71 by interacting with their respective viral surfaces (glycoprotein gp120 of HIV and the fivefold axis of the EV-A71 capsid). The high potency, low toxicity, facile chemical synthesis, and great opportunities for chemical optimization make them useful prototypes for future medicinal chemistry studies., This work was supported by the Spanish Plan Nacional (Subprograma Retos) [projects SAF2015-64629-C2-1-R and SAF2015-64629-C2-2-R (MINECO/FEDER)], the Spanish “Ministerio de Ciencia, Innovación y Universidades” (project PID2019-104070RB-C21), and by the Spanish Agencia Estatal Consejo Superior de Investigaciones Cientifí cas (CSIC, Projects CSIC-PIE-201980E100 and CSIC-PIE- 201980E028), “The Centers of Excellence” of the KU Leuven (EF-05/15 and PF-10/18), EU FP7 (FP7/2007−2013) Project EUVIRNA (Grant 408 Agreement 264286), EU FP7 SILVER (Contract HEALTH-F3-2010-260644), a grant from the Belgian Interuniversity Attraction Poles (IAP) Phase VIIP7/ 45 (BELVIR), and the EU FP7 Industry-Academia Partnerships and Pathways Project AIROPICO. The Spanish MEC/MINECO is also acknowledged for grants to B.M.-G. and O.M.-M. and the China Scholarship Council (CSC) (grant 201403250056) for a grant to L.S. S.H. received a grant from the Pennsylvania Department of Health using Tobacco CURE Funds. We also thank Charlotte Vanderheydt, Sandra Claes, and Evelyne Van Kerckhove for helping with the processing of the antiviral data. This work has been awarded with the Janssen (XVIII call) and Esteve (XIX call) prizes within the “Prizes for Young Researchers of the Spanish Society of Medicinal Chemistry (SEQT)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Insertion of an Amphipathic Linker in a Tetrapodal Tryptophan Derivative Leads to a Novel and Highly Potent Entry Inhibitor of Enterovirus A71 Clinical Isolates

  • Martí-Marí, Olaia
  • Abdelnabi, Rana
  • Schols, Dominique
  • Neyts, Johan
  • Camarasa Rius, María José
  • Gago, Federico
  • San-Félix, Ana
AL-471, the leading exponent of a class of potent HIV and enterovirus A71 (EV-A71) entry inhibitors discovered in our research group, contains four l-tryptophan (Trp) units bearing an aromatic isophthalic acid directly attached to the C2 position of each indole ring. Starting from AL-471, we (i) replaced l-Trp with d-Trp, (ii) inserted a flexible linker between C2 and the isophthalic acid, and (iii) substituted a nonaromatic carboxylic acid for the terminal isophthalic acid. Truncated analogues lacking the Trp motif were also synthesized. Our findings indicate that the antiviral activity seems to be largely independent of the stereochemistry (l- or d-) of the Trp fragment and also that both the Trp unit and the distal isophthalic moiety are essential for antiviral activity. The most potent derivative, 23 (AL-534), with the C2 shortest alkyl urea linkage (three methylenes), showed subnanomolar potency against different EV-71 clinical isolates. This finding was only observed before with the early dendrimer prototype AL-385 (12 l-Trp units) but remained unprecedented for the reduced-size prototype AL-471. Molecular modeling showed the feasibility of high-affinity binding of the novel l-Trp-decorated branches of 23 (AL-534) to an alternative site on the VP1 protein that harbors significant sequence variation among EV-71 strains., This research was funded by the Spanish MICINN (Projects PID2019-104070RB-C21 and PID2019-104070RB-C22 (AEI/10.13039/501100011033)), and by the Spanish Agencia Estatal Consejo Superior de Investigaciones Científicas (CSIC, Projects CSIC-PIE-201980E100 and CSIC-PIE-201980E028), “The Centers of Excellence” of the KU Leuven (EF-05/15 and PF-10/18), EU FP7 (FP7/2007–2013) Project EUVIRNA (Grant 408 Agreement 264286), EU FP7 SILVER (Contract HEALTH-F3-2010-260644), a grant from the Belgian Interuniversity Attraction Poles (IAP) Phase VII–P7/45 (BELVIR), and the EU FP7 Industry–Academia Partnerships and Pathways Project AIROPICO. The Spanish MEC/MINECO also funded a grant to O.M.-M., Peer reviewed